MZL and Ibrutinib
Research is underway in some of the smaller subtypes of lymphoma. This phase II, open label non-randomised study is evaluating the safety and efficacy of ibrutinib in those with relapsed or refractory marginal zone lymphoma.
Patients (n = 60) will be enrolled from approximately 32 sites in Belgium, France, Germany, the UK and the USA. Please let your members know about this clinical trial. For more information, click here to read the full article.